Cost-effectiveness in the treatment of schizophrenia.
This paper discusses the need for a health economics perspective and some of the central methodological issues raised by economic appraisals, including cost-effectiveness and cost-utility analyses. It illustrates how cost-effectiveness studies can inform policy and practice decisions concerning the treatment of schizophrenia, focusing on five generic evaluation questions commonly raised. Examples are drawn from recent and current UK research.
Knapp
M
M
Centre for the Economics of Mental Health, Institute of Psychiatry, University of London, 7 Windsor Walk, Denmark Hill, London SE5 8BB, UK; Personal Social Services Research Unit, London School of Economics, UK.